Status:
COMPLETED
Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer
Lead Sponsor:
Jules Bordet Institute
Conditions:
Invasive Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
In this prospective study the investigators sought to evaluate the feasibility of using the genomic signature - Genomic Grade Index (GGI) - in routine clinical practice and its impact on treatment rec...
Detailed Description
The primary objective of this study was to evaluate the feasibility of implementing Genomic Grade Index (GGI) in community hospitals in Belgium for breast cancer patients with node negative and 1-3 no...
Eligibility Criteria
Inclusion
- Histologically confirmed invasive breast cancer meeting the following criteria:
- T1, T2, or operable T3 disease
- Zero to three positive lymph nodes and no distant metastases
- Operable disease - Must have undergone breast-conserving surgery or mastectomy with either a sentinel node procedure or full axillary clearance
Exclusion
- No other invasive cancer within the past 5 years except for adequately treated carcinoma in situ of the cervix or non melanoma skin cancer
- No psychological, familial, sociological, or geographical condition that would preclude entering into a clinical study
Key Trial Info
Start Date :
February 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT01916837
Start Date
February 1 2010
End Date
December 1 2010
Last Update
August 6 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Jules Bordet
Brussels, Belgium, 1000